Motor and Functional Improvement in a 71-Year-Old Parkinson’s Disease Patient Following a Series of Intravenous Nanobubble and Methylene Blue Therapy: A Case Report

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss, mitochondrial dysfunction, and oxidative stress. Current therapies focus largely on symptom relief without modifying disease progression. Novel interventions targeting mitochondrial health and redox balance, such as methylene blue (MB) and nanobubble-based therapies, offer emerging therapeutic potential. Case Report: A 71-year-old male with a 22-year history of idiopathic PD (Hoehn & Yahr stage III) received 48 intravenous infusion sessions over 70 days. The regimen included hydrogen–oxygen nanobubbles, gasotransmitters (e.g., nitric oxide), and titrated doses of MB. Baseline medications were continued unchanged throughout therapy. Quantitative assessments demonstrated a clinically significant improvement: the UPDRS-III motor score decreased from 28 to 18 (−35.71%), Timed Up and Go (TUG) time improved from 15 to 3 seconds, and 10-Meter Walk Test (10MWT) speed increased from 0.5 m/s to 1.0 m/s. The patient also reported enhanced stamina, clearer speech, and reduced tremor. No serious adverse events occurred. Conclusion: This case supports the potential of combined nanobubble and methylene blue therapy as a promising adjunct in PD treatment. Notable improvements in motor function and quality of life were observed without adverse effects. While these results are encouraging, further validation through controlled clinical trials is warranted to assess efficacy, safety, and underlying mechanisms.

Related topics